Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag124 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.04.2026. Verfasst von Pengcheng Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Cholangiocarcinoma, Neoplasm Recurrence, Local, Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Technical Standard Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
IDH1 mutations are causal in tumor development and progression; however, their association with disease characteristics, prognosis, and therapy response in patients with resected intrahepatic cholangiocarcinoma (ICC) remains controversial. Materials and Methods In this cohort study, we recruited 803 patients who underwent curative resection for ICC at a single hospital in China. We performed whole-exome sequencing and Sanger sequencing to identify IDH1 mutations. We used the Kaplan–Meier method and log-rank test to compare overall survival (OS) and disease-free survival (DFS).
Results
A total of 5 different subtypes of IDH1 somatic mutation affecting 94 (11.7%) patients were identified. R132C was the most frequent mutant allele in this cohort, followed by R132L and R132G. Across all patients considered, those that received adjuvant chemotherapy had significantly superior OS and DFS compared with those that did not receive adjuvant chemotherapy. In the whole ICC cohort, patients with IDH1 mutations showed no significant difference in OS compared with patients with wild-type IDH1. When we looked at patients that either received or did not receive adjuvant chemotherapy separately, univariate and multivariable analyses revealed that IDH1 mutations were significantly associated with superior OS among patients that received adjuvant chemotherapy, whereas they were marginally associated with worse OS among patients that did not receive adjuvant chemotherapy.
Conclusion
We characterized the distribution of IDH1 mutations in a large cohort of patients with ICC from China. The presence of IDH1 mutations was associated with better survival and decreased risk of recurrence in patients with resected ICC that received adjuvant chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Institute for Ovarian Cancer, Fudan University & Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai 200032, China.
- Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
ORCID-Profile: Shaolai Zhou
Förderung
- National Natural Science Foundation of China
- Shanghai Technical Standard Program
Zitieren
APA
Wang, P., Li, N., Ye, Y., Pu, J., Sun, R., Luo, C., Hu, Z., Zhou, Z., Li, J., Zou, J., Fan, J., Zhou, J., & Zhou, S. (2026). Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag124
Vancouver
Wang P, Li N, Ye Y, Pu J, Sun R, Luo C, et al. Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag124
BibTeX
@article{Wang2026,
author = {Wang, Pengcheng and Li, Ning and Ye, Yuhang and Pu, Jing and Sun, Rongqi and Luo, Chubin and Hu, Zhiqiang and Zhou, Zhengjun and Li, Jia and Zou, Jixue and Fan, Jia and Zhou, Jian and Zhou, Shaolai},
title = {Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag124}
}
EUVIMED